HADH and gastric cancer: Shen et al. (2017) showed that downregulation of HADH was significantly correlated with advanced clinical stage, low overall survival (OS), low disease-free survival (DFS), and poor clinical prognosis. Hence, HADH expression has been proposed as an independent prognostic factor that affects patient survival rates. Mechanistically, reduced HADH expression significantly promoted cell proliferation and increased migration and invasion of tumor cells in vitro; in contrast, overexpression of HADH inhibited the proliferation of gastric cancer cells (Shen et al., 2017).